ClinicalTrials.gg

Program

nintedanib

Also written as “Nintedanib”, “BIBF 1120” and “Nintedanib (BIBF1120)”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Carcinoma, Non-Small-Cell Lung · Pulmonary Fibrosis · Lung Diseases, Interstitial · Neoplasms, led by 3 companies.

Furthest: phase 4, since Oct 16, 201564 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim620 open or runningphase 4since Oct 16, 2015Aug 9, 2007none ahead
Mannkind10 open or runningphase 1since Jan 7, 2026Jan 7, 2026none ahead
PureTech10 open or runningphase 1since Nov 20, 2024Nov 20, 2024none ahead

Also a collaborator on its studies: novotech-australia-pty-limited and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Aug 5, 2008.

  1. Apr 22, 2016Phase 1 study in Carcinoma, Non-Small-Cell LungBoehringer Ingelheim · NCT02751385 · 2 enrolled · Germany
  2. May 20, 2016Phase 2 study in Colorectal NeoplasmsBoehringer Ingelheim · NCT02780700 · 1 enrolled · United States
  3. May 27, 2016Phase 4 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT02788474 · 347 enrolled · United States, Australia, Belgium and more
  4. Dec 19, 2016Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT02999178 · 663 enrolled · United States, Argentina, Belgium and more
  5. Oct 13, 2017Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT03313180 · 444 enrolled · United States, Argentina, Australia and more
  6. Sep 17, 2018Phase 1 study in Scleroderma, SystemicBoehringer Ingelheim · NCT03675581 · 17 enrolled · Belgium, France, Germany and more
  7. Jan 28, 2019Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT03820726 · 435 enrolled · United States, Argentina, Belgium and more
  8. Sep 16, 2019Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT04093024 · 39 enrolled · United States, Argentina, Australia and more
  9. Jun 23, 2021Phase 1 study in HealthyBoehringer Ingelheim · NCT04938453 · 20 enrolled · Germany
  10. Sep 30, 2021Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT05065190 · 81 enrolled · China
  11. Mar 10, 2022Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT05285982 · 54 enrolled · United States, Argentina, Belgium and more
  12. Oct 2, 2023Phase 1 study in HealthyBoehringer Ingelheim · NCT06070610 · 14 enrolled · Germany
  13. Nov 20, 2024PureTech's first study: phase 1 study in Pulmonary FibrosisNew to PureTechPureTech · NCT06717100 · 24 enrolled · Australia
  14. Jan 7, 2026Mannkind's first study: phase 1 study in Idiopathic Pulmonary FibrosisNew to MannkindMannkind · NCT07344558 · 27 enrolled · United States

TargetBeta

“Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 64 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07344558Idiopathic Pulmonary Fibrosis · United States1CompletedMannkindJun 17, 202627
NCT06717100Pulmonary Fibrosis · Australia1CompletedPureTechFeb 17, 202524
NCT06070610Healthy · Germany1CompletedBoehringer IngelheimDec 14, 202314
NCT05285982Lung Diseases, Interstitial · United States, Argentina, Belgium and more3CompletedBoehringer IngelheimAug 13, 202554
NCT05065190Lung Diseases, Interstitial · China3CompletedBoehringer IngelheimApr 30, 202481
NCT04938453Healthy · Germany1CompletedBoehringer IngelheimAug 30, 202120
NCT04093024Lung Diseases, Interstitial · United States, Argentina, Australia and more3CompletedBoehringer IngelheimMay 24, 202239
NCT03820726Lung Diseases, Interstitial · United States, Argentina, Belgium and more3CompletedBoehringer IngelheimAug 30, 2022435
NCT03675581Scleroderma, Systemic · Belgium, France, Germany and more1CompletedBoehringer IngelheimOct 9, 201917
NCT03313180Lung Diseases, Interstitial · United States, Argentina, Australia and more3CompletedBoehringer IngelheimJan 25, 2023444
NCT02999178Lung Diseases, Interstitial · United States, Argentina, Belgium and more3CompletedBoehringer IngelheimApr 23, 2019663
NCT02788474Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more4CompletedBoehringer IngelheimAug 4, 2017347
NCT02780700Colorectal Neoplasms · United States2TerminatedBoehringer IngelheimSep 9, 20161
NCT02751385Carcinoma, Non-Small-Cell Lung · Germany1TerminatedBoehringer IngelheimNov 28, 20172
NCT02668393Carcinoma, Non-Small-Cell Lung · France, Germany1CompletedBoehringer IngelheimNov 27, 201914
NCT02667704Healthy · Germany1CompletedBoehringer IngelheimMar 201613
NCT02606877Idiopathic Pulmonary Fibrosis · United Kingdom4CompletedBoehringer IngelheimMar 22, 201737
NCT02579603Idiopathic Pulmonary Fibrosis · United States, Canada, France and more4CompletedBoehringer IngelheimJan 3, 2017105
NCT02597933Scleroderma, Systemic · United States, Argentina, Australia and more3CompletedBoehringer IngelheimOct 31, 2018580
NCT02572752Healthy · Germany1CompletedBoehringer IngelheimNov 201570
NCT02300298Carcinoma, Non-Small-Cell Lung · Japan1CompletedBoehringer IngelheimJan 15, 201610
NCT02231164Carcinoma, Non-Small-Cell Lung · United States, Georgia, Thailand3TerminatedBoehringer IngelheimDec 24, 201512
NCT02191865Hepatic Insufficiency · Germany1CompletedBoehringer IngelheimDec 201433
NCT02182258Healthy1CompletedBoehringer IngelheimAug 200930
NCT02182245Genital Neoplasms, Female1CompletedBoehringer IngelheimJan 1, 200722
NCT02182219Prostatic Neoplasms1CompletedBoehringer IngelheimApr 1, 200721
NCT02182206Neoplasms1CompletedBoehringer IngelheimJun 200550
NCT02182193Healthy1CompletedBoehringer IngelheimNov 200654
NCT02182154Healthy1CompletedBoehringer IngelheimNov 20058
NCT02182141Multiple Myeloma1CompletedBoehringer IngelheimMar 200517
NCT02182128Neoplasms1CompletedBoehringer IngelheimJun 200924
NCT02182102Carcinoma, Non-Small-Cell Lung1CompletedBoehringer IngelheimMay 201026
NCT02182076Healthy1CompletedBoehringer IngelheimNov 200515
NCT02182063Prostatic Neoplasms2CompletedBoehringer IngelheimJan 200781
NCT02182050Carcinoma, Non-Small-Cell Lung2CompletedBoehringer IngelheimJan 200773
NCT02149108Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedBoehringer IngelheimMay 13, 2016768
NCT01979952Idiopathic Pulmonary Fibrosis · United States, Canada, Turkey3CompletedBoehringer IngelheimOct 27, 2016113
NCT01951846Malignant Solid Tumour · Germany1CompletedBoehringer IngelheimNov 200461
NCT01907100Mesothelioma · United States, Argentina, Australia and more3TerminatedBoehringer IngelheimMar 16, 2018545
NCT01770392Healthy · Germany1CompletedBoehringer IngelheimMar 201326
NCT01679613Healthy · Germany1CompletedBoehringer IngelheimNov 201234
NCT01619085Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more3CompletedBoehringer IngelheimJul 5, 2017752
NCT01594125Carcinoma, Hepatocellular · Japan1CompletedBoehringer IngelheimNov 201430
NCT01417156Pulmonary Fibrosis · Japan2CompletedBoehringer IngelheimOct 201520
NCT01346540Carcinoma, Non-Small-Cell Lung · Italy, Netherlands, Spain and more1CompletedBoehringer IngelheimApr 25, 201316
NCT01335477Pulmonary Fibrosis · United States, Canada, Chile and more3CompletedBoehringer IngelheimOct 2013551
NCT01335464Pulmonary Fibrosis · United States, Australia, Belgium and more3CompletedBoehringer IngelheimOct 2013515
NCT01170065Pulmonary Fibrosis · Argentina, Australia, Belgium and more2CompletedBoehringer IngelheimSep 26, 2016198
NCT01136174Idiopathic Pulmonary Fibrosis · Japan2CompletedBoehringer IngelheimMar 201150
NCT01022853Neoplasms · Italy1CompletedBoehringer IngelheimFeb 201330
NCT01024920Carcinoma, Renal Cell · Hungary, Poland, Romania and more2CompletedBoehringer IngelheimNov 8, 201199
NCT01015118Ovarian Neoplasms · United States, Australia, Austria and more3CompletedBoehringer IngelheimApr 1, 20131,366
NCT00998296Neoplasms · France1CompletedBoehringer IngelheimDec 201270
NCT01004003Carcinoma, Hepatocellular · Austria, France, Germany and more2CompletedBoehringer IngelheimJul 14, 2014125
NCT00987935Carcinoma, Hepatocellular · Korea, Republic of, Taiwan2CompletedBoehringer IngelheimJul 2014134
NCT00979576Carcinoma, Non-Small-Cell Lung · Japan1TerminatedBoehringer IngelheimFeb 16, 201519
NCT00806819Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedBoehringer IngelheimJun 2011718
NCT00805194Carcinoma, Non-Small-Cell Lung · Austria, Belarus, Belgium and more3CompletedBoehringer IngelheimNov 2, 20101,314
NCT00801294Colorectal Neoplasms · France2CompletedBoehringer IngelheimNov 1, 200746
NCT00730821Neoplasms · United States1CompletedBoehringer IngelheimAug 200928

How it is read

Names in the registry

  • “Nintedanib”, 43 entries
  • “BIBF 1120”, 26 entries
  • “nintedanib”, 4 entries
  • “Nintedanib (BIBF1120)”, 2 entries
  • “Nintedanib high dose”, 2 entries

Codes read as this program: MNKD201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.